{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:49:33Z","timestamp":1789764573686,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hospitalized patients with non-severe community-acquired pneumonia (CAP) are treated with a \u03b2-lactam plus either a macrolide or doxycycline. Limited data exist on the effectiveness of the latter combination. Therefore, we aimed to compare the combination of doxycycline vs. macrolide when either is combined with a \u03b2-lactam from effectiveness and safety perspectives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective cohort study in CAP inpatients between December 2013 and November 2020. Patients were divided into BL-D (\u03b2-lactam plus doxycycline) and BL-M (\u03b2-lactam plus a macrolide [azithromycin or clarithromycin]) groups. The primary endpoint was time to clinical stability. Secondary endpoints included length of stay (LOS) and in-hospital mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 197 patients included, 57 were in the BL-D arm and 140 were in the BL-M arm. Patients were similar at baseline, except for the presence of leukocytosis, risk factors for drug resistance, and duration of therapy (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05 for all comparisons). No difference in clinical cure rate was observed (94.7% vs. 91.4%; <jats:italic>P<\/jats:italic>\u2009=\u20090.43). Time to clinical stability and LOS were similar in both groups at 4 (<jats:italic>P<\/jats:italic>\u2009=\u20090.82) and 7\u00a0days (<jats:italic>P<\/jats:italic>\u2009=\u20090.62), respectively. While only three patients died, only one (from the BL-M group) was due to sepsis. Liver enzymes elevation was more prominent in the BL-M group (21.4% vs. 5.3%; <jats:italic>P<\/jats:italic>\u2009=\u20090.01). A subgroup analysis showed shorter time to clinical stability with clarithromycin but higher cure rates with azithromycin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Data on doxycycline use with a \u03b2-lactam are scarce. Our study showed that such regimen was comparable in effectiveness to regimens involving macrolides with a better safety profile.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00912-8","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T12:02:59Z","timestamp":1670500979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Doxycycline vs. macrolides in combination with a \u03b2-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients"],"prefix":"10.1186","volume":"27","author":[{"given":"Raghad K.","family":"Aldhahri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad G.","family":"Gabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohoud A.","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M.","family":"Almadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Eljaaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar K.","family":"Thabit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"5","key":"912_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/bjaed\/mkv052","volume":"16","author":"AJ Morgan","year":"2016","unstructured":"Morgan AJ, Glossop AJ. Severe community-acquired pneumonia. BJA Educ. 2016;16(5):167\u201372. https:\/\/doi.org\/10.1093\/bjaed\/mkv052.","journal-title":"BJA Educ"},{"issue":"49","key":"912_CR2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3238\/arztebl.2017.0838","volume":"114","author":"M Kolditz","year":"2017","unstructured":"Kolditz M, Ewig S. Community-acquired pneumonia in adults. Dtsch Arztebl Int. 2017;114(49):838\u201348. https:\/\/doi.org\/10.3238\/arztebl.2017.0838.","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"912_CR3","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia an official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367. https:\/\/doi.org\/10.1164\/rccm.201908-1581ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"912_CR4","volume-title":"Doxycycline hyclate","author":"RS Patel","year":"2020","unstructured":"Patel RS, Parmar M. Doxycycline hyclate. Treasure Island (FL): StatPearls; 2020."},{"key":"912_CR5","volume-title":"Macrolides","author":"PH Patel","year":"2020","unstructured":"Patel PH, Hashmi MF. Macrolides. Treasure Island (FL): StatPearls; 2020."},{"issue":"1","key":"912_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jhm.8","volume":"1","author":"SA Flanders","year":"2006","unstructured":"Flanders SA, Dudas V, Kerr K, McCulloch CE, Gonzales R. Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia. J Hosp Med. 2006;1(1):7\u201312. https:\/\/doi.org\/10.1002\/jhm.8.","journal-title":"J Hosp Med"},{"issue":"4","key":"912_CR7","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1111\/j.1469-0691.2011.03759.x","volume":"18","author":"B Teh","year":"2012","unstructured":"Teh B, Grayson ML, Johnson PD, Charles PG. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Clin Microbiol Infect. 2012;18(4):E71\u20133. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03759.x.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"912_CR8","first-page":"1014","volume":"43","author":"B Wiesner","year":"1993","unstructured":"Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung. 1993;43(9):1014\u20137.","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"912_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/archinte.159.3.266","volume":"159","author":"RK Ailani","year":"1999","unstructured":"Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1999;159(3):266\u201370. https:\/\/doi.org\/10.1001\/archinte.159.3.266.","journal-title":"Arch Intern Med"},{"issue":"2","key":"912_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","volume":"35","author":"R Mokabberi","year":"2010","unstructured":"Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther. 2010;35(2):195\u2013200. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01073.x.","journal-title":"J Clin Pharm Ther"},{"key":"912_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcm10194321","volume":"10","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly K, Aljabri A, Rabaan AA, Aljuhani O, Thabit AK, Alshibani M, et al. Efficacy of empiric antibiotic coverage in community-acquired pneumonia associated with each atypical bacteria: a meta-analysis. J Clin Med. 2021;10:19. https:\/\/doi.org\/10.3390\/jcm10194321.","journal-title":"J Clin Med"},{"issue":"1","key":"912_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2019.1680116","volume":"32","author":"K Eljaaly","year":"2020","unstructured":"Eljaaly K, Botaish A, Bahobail F, Almehmadi M, Assabban Z, Thabit AK, et al. Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia. J Chemother. 2020;32(1):1\u20136. https:\/\/doi.org\/10.1080\/1120009X.2019.1680116.","journal-title":"J Chemother"},{"key":"912_CR13","doi-asserted-by":"publisher","first-page":"2135239","DOI":"10.1155\/2020\/2135239","volume":"2020","author":"AI Edhi","year":"2020","unstructured":"Edhi AI, Hakim S, Shams C, Bedi D, Amin M, Cappell MS. Clarithromycin-associated acute liver failure leading to fatal, massive upper gastrointestinal hemorrhage from profound coagulopathy: case report and systematic literature review. Case Reports Hepatol. 2020;2020:2135239. https:\/\/doi.org\/10.1155\/2020\/2135239.","journal-title":"Case Reports Hepatol"},{"issue":"2","key":"912_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1469-0691.2006.01633.x","volume":"13","author":"M Tamm","year":"2007","unstructured":"Tamm M, Todisco T, Feldman C, Garbino J, Blasi F, Hogan P, et al. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin Microbiol Infect. 2007;13(2):162\u201371. https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01633.x.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"912_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s100960050201","volume":"17","author":"B O'Doherty","year":"1998","unstructured":"O\u2019Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia azithromycin study group. Eur J Clin Microbiol Infect Dis. 1998;17(12):828\u201333. https:\/\/doi.org\/10.1007\/s100960050201.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"912_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1179\/joc.2004.16.1.102","volume":"16","author":"N Sopena","year":"2004","unstructured":"Sopena N, Martinez-Vazquez C, Rodriguez-Suarez JR, Segura F, Valencia A, Sabria M. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J Chemother. 2004;16(1):102\u20133. https:\/\/doi.org\/10.1179\/joc.2004.16.1.102.","journal-title":"J Chemother"},{"issue":"3","key":"912_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1183\/09031936.95.08030398","volume":"8","author":"G Rizzato","year":"1995","unstructured":"Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J. 1995;8(3):398\u2013402. https:\/\/doi.org\/10.1183\/09031936.95.08030398.","journal-title":"Eur Respir J"},{"issue":"12","key":"912_CR18","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3855\/jidc.12741","volume":"14","author":"RO Al-Madfaa","year":"2020","unstructured":"Al-Madfaa RO, Alalawi MA, Basudan LO, Alhejaili SF, Eljaaly K, Madani TA, et al. Dual versus triple therapy for uncomplicated brucellosis: a retrospective cohort study. J Infect Dev Ctries. 2020;14(12):1380\u20136. https:\/\/doi.org\/10.3855\/jidc.12741.","journal-title":"J Infect Dev Ctries"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00912-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T12:10:49Z","timestamp":1670501449000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00912-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00912-8","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Research Committee of the Biomedical Ethics Unit of the Faculty of Medicine at King Abdulaziz University, Jeddah, Saudi Arabia (Reference No. 459\u201320), who also waived the requirement to obtain informed consent, since the study was retrospective. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}